Cargando…

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

BACKGROUND: Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety and tolerability. However, little is known about possible predictors, dose dependence and ti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schenk, Hannah, Holle, Dagny, Nsaka, Michael, Kleinschnitz, Christoph, Glas, Martin, Scheffler, Armin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092816/ https://www.ncbi.nlm.nih.gov/pubmed/35538414 http://dx.doi.org/10.1186/s10194-022-01426-8

Ejemplares similares

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
por: Scheffler, Armin, et al.
Publicado: (2020)

CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience
por: Scheffler, Armin, et al.
Publicado: (2021)

Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies
por: Nsaka, Michael, et al.
Publicado: (2022)

Reduced vestibular perception thresholds in persistent postural-perceptual dizziness- a cross-sectional study
por: Wurthmann, Sebastian, et al.
Publicado: (2021)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Recent advances in the management of migraine
por: Obermann, Mark, et al.
Publicado: (2016)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine
por: Katsuki, Masahito, et al.
Publicado: (2023)

Efficacy and safety of erenumab in women with a history of menstrual migraine
por: Pavlovic, Jelena M., et al.
Publicado: (2020)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
por: Manickam, Agaath Hedina, et al.
Publicado: (2021)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment
por: Pilati, Laura, et al.
Publicado: (2023)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

A prospective real-world analysis of erenumab in refractory chronic migraine
por: Lambru, Giorgio, et al.
Publicado: (2020)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine
por: Silvestro, Marcello, et al.
Publicado: (2021)

MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
por: Belvís, Robert, et al.
Publicado: (2021)

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
por: Alsaadi, Taoufik, et al.
Publicado: (2022)

Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report
por: Jantzen, Frederik Thal, et al.
Publicado: (2023)

Predictors of response to erenumab after 12 months of treatment
por: Baraldi, Carlo, et al.
Publicado: (2021)

Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
por: Schoenen, Jean, et al.
Publicado: (2021)

One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial
por: Tepper, Stewart J., et al.
Publicado: (2019)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials
por: Di Tanna, Gian Luca, et al.
Publicado: (2019)

Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series
por: Ornello, Raffaele, et al.
Publicado: (2021)

Impact of COVID-19 on chronic migraine treated with erenumab: a case report
por: Grassini, Alberto, et al.
Publicado: (2021)

A real‐world, observational study of erenumab for migraine prevention in Canadian patients
por: Becker, Werner J., et al.
Publicado: (2022)

A TWELVE MONTH CLINICAL TRIAL OF CHIROPRACTIC SPINAL MANIPULATIVE THERAPY FOR MIGRAINE
por: Tuchin, Peter J.
Publicado: (1999)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
por: Lowe, Michael, et al.
Publicado: (2022)

Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials
por: Lampl, Christian, et al.
Publicado: (2022)

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
por: Raffaelli, Bianca, et al.
Publicado: (2020)

Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
por: Ornello, Raffaele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s7bv3t9g77vu8cdb7gcs652pii